Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**740 Y-P is a synthetic cell-permeable phosphopeptide that acts as a potent activator of phosphoinositide 3-kinase (PI3K).** It is designed to mimic the phosphorylated tyrosine motif found in the platelet-derived growth factor receptor (PDGFR), specifically at position Tyr-740. The peptide sequence includes an Antennapedia protein transduction domain to facilitate cellular uptake. Mechanistically, it binds to the SH2 domains of the p85 regulatory subunit of PI3K and stimulates PI3K activity both in vitro and in vivo. This activation leads to downstream signaling through pathways such as PI3K/Akt/mTOR and can stimulate mitogenesis even at low concentrations[1][2][5][9]. In research models, it has been shown to increase phosphorylation of AKT and PI3K and reduce reactive oxygen species levels in neuronal tissue[5]. Its primary use is as a biochemical tool for studying signal transduction related to cell proliferation, survival, autophagy modulation, apoptosis inhibition, and neuroprotection. It is not approved for clinical or therapeutic use; all applications are limited strictly to laboratory research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 740 Y-P.